Published

Aim: This study was to investigate the diagnostic value by using Liver stiffness measurement (LSM) measured by FibroScan in patients with hepatocellular carcinoma (HCC).Methods: There were 48 patients with HCC who underwent LSM using FibroScan (Each patient was detected in 5 different sites.) between June 2021 and February 2022 were enrolled in this research.LSM failure defined as zero valid shots (unsuccessful LSM), or the ratio of the interquartile range to the median of 10 measurements (IQR/M) greater than 0.30 plus success rate (SR) less than 60% (unreliable LSM).Results: The mean age of the patients (42 men, 6 women) was 53.3 ± 11.6 years, with a mean body mass index of 22.8.A total of 240 measurements were done and 141 valid values were obtained with failure rates of 41.3%.Among them, there were 19 patients (19.2%) with unsuccessful LSM, 37 patients (37.4%) with SR<60%, 59 (59.6%) with IQR/M > 30%.In all the five measurements of each patient, 5 reliable results were got in 10 cases, 4 in 15 cases, 3 in 8 cases, 2 in 7 cases, 1 in 6 cases, and 0 in 2 cases, respectively.LSM values of all the HCC patients were 27.7 (14.1-75.0)kPa.Conclusion: LSM are often accompanied by a high rate of failure in HCC patients.Nodules in HCC patients lead to the inhomogeneity of liver parenchyma, and thus results of IQR/M rise.FibroScan through multipoint measurement are helpful to screen or identify HCC.